Skip to main content
. Author manuscript; available in PMC: 2014 Sep 9.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2

Comparison 3. Mirtazapine versus SNRIs.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Primary outcome (response) at 2 weeks 2 415 Odds Ratio (M-H, Random, 95% CI) 2.29 [1.45, 3.59]
 1.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 2.29 [1.45, 3.59]
2 Primary outcome (response) at end of the acute-phase treatment 2 415 Odds Ratio (M-H, Random, 95% CI) 1.53 [1.03, 2.25]
 2.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 1.53 [1.03, 2.25]
3 Secondary outcome (remission) at 2 weeks 2 415 Odds Ratio (M-H, Random, 95% CI) 2.34 [1.07, 5.13]
 3.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 2.34 [1.07, 5.13]
4 Secondary outcome (remission) at end of the acute-phase treatment 2 415 Odds Ratio (M-H, Random, 95% CI) 1.55 [0.98, 2.47]
 4.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 1.55 [0.98, 2.47]
5 Secondary outcome (withdrawal due to any reason) 2 415 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.43, 0.99]
 5.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.43, 0.99]
6 Secondary outcome (withdrawal due to adverse events) 2 415 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.24, 1.24]
 6.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.24, 1.24]
7 Secondary outcome (having some adverse events) 1 157 Odds Ratio (M-H, Random, 95% CI) 1.51 [0.76, 3.00]
 7.1 vs Venlafaxine 1 157 Odds Ratio (M-H, Random, 95% CI) 1.51 [0.76, 3.00]
8 Hypotension/Bradycardia 1 157 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.68]
 8.1 vs Venlafaxine 1 157 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.68]
9 Sweating 1 157 Odds Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.45]
 9.1 vs Venlafaxine 1 157 Odds Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.45]
10 Constipation 1 157 Odds Ratio (M-H, Random, 95% CI) 0.22 [0.06, 0.83]
 10.1 vs Venlafaxine 1 157 Odds Ratio (M-H, Random, 95% CI) 0.22 [0.06, 0.83]
11 Dry mouth/Decreased salivation 2 415 Odds Ratio (M-H, Random, 95% CI) 8.61 [0.35, 211.85]
 11.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 8.61 [0.35, 211.85]
12 Nausea/Vomiting/Gastric distress 2 415 Odds Ratio (M-H, Random, 95% CI) 0.11 [0.00, 9.34]
 12.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 0.11 [0.00, 9.34]
13 Anxiety/Agitation 1 157 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.24, 4.20]
 13.1 vs Venlafaxine 1 157 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.24, 4.20]
14 Fatigue/Tiredness/Asthenia 1 258 Odds Ratio (M-H, Random, 95% CI) 2.43 [1.30, 4.55]
 14.1 vs Venlafaxine 1 258 Odds Ratio (M-H, Random, 95% CI) 2.43 [1.30, 4.55]
15 Headache 2 415 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.53, 1.72]
 15.1 vs Venlafaxine 2 415 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.53, 1.72]
16 Sleep disturbance 1 258 Odds Ratio (M-H, Random, 95% CI) 0.02 [0.00, 0.41]
 16.1 vs Venlafaxine 1 258 Odds Ratio (M-H, Random, 95% CI) 0.02 [0.00, 0.41]
17 Sleepiness/Drowsiness/Somnolence 1 157 Odds Ratio (M-H, Random, 95% CI) 1.56 [0.42, 5.77]
 17.1 vs Venlafaxine 1 157 Odds Ratio (M-H, Random, 95% CI) 1.56 [0.42, 5.77]
18 Completed suicide 1 157 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.31]
 18.1 vs Venlafaxine 1 157 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.31]